Qbic II

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

Laminaria, founded in 2011 and based in Ostend, Belgium, specializes in manufacturing wave energy converter equipment. The company is at the forefront of developing technology designed to harness renewable wave energy, using a system that converts tilting and translating motions into power through mooring ropes connected to generators. Laminaria leads the LAMWEC project, a consortium of ocean energy experts that includes organizations such as EMEC, Innosea, Ghent University, and TTI Testing. Through its innovative technology, Laminaria aims to significantly impact the renewable energy landscape by advancing the effectiveness and efficiency of wave energy conversion.